Some Much-Needed CONFIDENCE to Combat the Risk-Treatment Paradox in Chronic Kidney Disease
This JACC commentary discussed the risk-treatment paradox in chronic kidney disease, where patients at highest cardiovascular risk are least likely to receive evidence-based therapies including SGLT2 inhibitors and statins.
Summary
Publication date: 24 February 2026Source: JACC, Volume 87, Issue 7
Join us
Join the Global Primary Care Cardio Network. Membership is free.
Would you like to tell us more about yourself?
Interests
We will send you an email with a link to confirm your registration.
